Opus Genetics shows promising gene therapy results restoring vision in inherited retinal diseases.

Opus Genetics presented new clinical and preclinical data at ARVO 2026 demonstrating significant progress in gene therapies for inherited retinal diseases. Their OPGx-LCA5 therapy restored cone-mediated vision in pediatric patients with Leber congenital amaurosis type 5, showing over 30-fold sensitivity improvements and better visual acuity. Additional programs targeting BEST1 and RHO mutations also showed positive outcomes, supporting broader treatment potential. These advancements highlight Opus Genetics' potential to offer durable, one-time treatments for genetic blindness, with further clinical data expected later in 2026.